MedTrace Logo

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

NCT06628362 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2026-04-17

No results posted yet for this study

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).

Conditions

  • Overweight or Obese
  • Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

Placebo

Placebo will be volume-matched and administered subcutaneously (SC) once weekly.

DRUG

Enicepatide

Enicepatide will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Carmot Therapeutics, Inc., a Member of the Roche Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-21
Primary Completion
2026-06-01
Completion
2026-09-24
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Canada
  • Mexico
  • New Zealand
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06628362 on ClinicalTrials.gov